Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint Plans To Seek Pharma Partners For Outcomes-Based Contracting: An Interview With WellPoint's Brian Sweet

Executive Summary

In an interview, "The Pink Sheet" talked to WellPoint Chief Pharmacy Officer Brian Sweet about the near-to-mid-term outlook for outcomes-based agreements between payers and drug manufacturers, including initiatives WellPoint is taking to work differently with biopharma (1"The Pink Sheet," May 24, 2010)

You may also be interested in...



Anthem Adds Lilly To Its Real-World Drug Outcomes Research Collaborations

The firms are still working to determine specific drugs or disease states to be studied under a five-year agreement. Speeding research dissemination may also be addressed.

HealthCore And AstraZeneca Big Data Initiative Pushes Ahead, But Will Lack of Trust Deter Additional Partners?

AstraZeneca and HealthCore, a subsidiary of Wellpoint, are halfway through a four-year agreement to study the effectiveness and economics of marketed drugs using real world evidence. The collaboration is making progress, but reaching some goals has been a challenge, says HealthCore CEO Marcus Wilson

ACOs Get In Gear, Accelerating Biopharma’s Value Imperative

Pharmaceutical companies have been reluctant to discuss their accountable care organization strategies, but the 32 “Pioneer” ACOs created this year could impact the way pharma develops and commercializes its drugs, and their influence will be felt well beyond their current Medicare remit.

Related Content

Topics

UsernamePublicRestriction

Register

PS052288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel